Study aims to cut leukemia treatment time in half for frail patients
NCT ID NCT07407660
Summary
This study is testing if a shorter treatment schedule is as effective and safer than the standard 28-day course for older or frail adults with acute myeloid leukemia (AML). It will enroll 250 patients who cannot tolerate strong chemotherapy. Doctors will check patients' bone marrow early and may stop one drug after 14 days if the cancer is responding well, hoping to reduce severe side effects like infections.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.